An anti-MITF small interfering RNA conjugated to a skin-penetrating peptide in a cream formulation was also successfully used for the treatment of patients with melasma, with an almost complete restoration of skin color on facial lesions after 12 weeks [110], but these agents need optimized topical delivery systems [111]
When patients start on these medications, they often experience nausea and vomiting
Use in Specific Populations (8.6).] When JANUVIA was used in combination with insulin or insulin secretagogues (e.g., sulfonylurea), medications known to cause hypoglycemia, the incidence of hypoglycemia was increased over that of placebo used in combination with a sulfonylurea or with insulin
Retrieved from Medline Plus
Beyond GLP-1s positive clinical impacts on diabetes and weight loss, were not well into a direct-to-patient (DTP) transformation that I believe is reshaping patients as health consumers in more proactive ways than weve seen before in the DTC era